CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
When should I offer lipid modification therapy for secondary prevention of cardiovascular disease?
- Offer lipid modification therapy to adults with cardiovascular disease (e.g. people with a past or current history of myocardial infarction, angina, stroke, transient ischaemic attack, or peripheral arterial disease).
In depth
© NHS Institute for Innovation and Improvement